



## AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference

July 16, 2018

MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- [AtriCure, Inc.](#) (Nasdaq: [ATRC](#)), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38<sup>th</sup> Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at [ir.atricure.com](#). A replay of the presentation will be available for 90 days following the presentation.

### About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. For more information, visit [AtriCure.com](#) or follow us on Twitter @[AtriCure](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180716005037/en/>

Source: AtriCure, Inc.

AtriCure, Inc.

Andy Wade, 513-755-4564

Senior Vice President and Chief Financial Officer

[awade@atricure.com](mailto:awade@atricure.com)

or

Gilmartin Group

Lynn Pieper Lewis, 415-937-5402

Investor Relations

[lynn@gilmartinir.com](mailto:lynn@gilmartinir.com)